{
    "clinical_study": {
        "@rank": "99190", 
        "arm_group": [
            {
                "arm_group_label": "VNS Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Vagus nerve stimulation and tones are used 2.5 hours per day for a 6-week period."
            }, 
            {
                "arm_group_label": "VNS Control", 
                "arm_group_type": "Sham Comparator", 
                "description": "Vagus nerve stimulation and tones are given daily over a 2.5 hour period, but not in the same way as the experimental group, and in such a way that it is believed to be ineffective but still provide both VNS and tones so that blinding is maintained."
            }
        ], 
        "brief_summary": {
            "textblock": "Assess the safety and efficacy of VNS paired with tones for tinnitus using a randomized,\n      controlled, parallel study design."
        }, 
        "brief_title": "Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Tinnitus", 
        "condition_browse": {
            "mesh_term": "Tinnitus"
        }, 
        "detailed_description": {
            "textblock": "Patients who have moderate to severe tinnitus, at least one year post diagnosis, may enroll.\n       All patients will be implanted and randomized to one of two groups:\n\n        -  a group receiving VNS paired with tones and;\n\n        -  a group that receives VNS and tones, but with different settings.\n\n      After device use training, therapy is delivered at home by the patient for 6 weeks.\n      Patients have eight baseline audiometric assessments along with two questionnaire\n      assessments, an assessment after recovery before treatment starts, and tinnitus assessments\n      every two weeks during therapy through the 6 week randomized portion of the study.  After\n      the randomized portion, all patients receive VNS paired with tones.  Patients will continue\n      to return for quarterly visits and tinnitus assessments through the first year after\n      implant, regardless of their therapy status.  Interested patients can continue to receive\n      longer-term treatment after the first year.  A goal of up to 30 patients enrolled and\n      implanted across four sites is planned for this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 22 to 65 years of age\n\n          2. Have been diagnosed as suffering from sensorineural tinnitus and at least some tonal\n             quality of the tinnitus\n\n          3. Unilateral or bilateral tinnitus\n\n          4. Have experienced tinnitus for at least one year and failed at least one  tinnitus\n             therapy (such as a counseling or sound therapy procedure.  The diagnosis of tinnitus\n             will include an audiological or medical diagnosis in their health records, as well as\n             a patient affirmation of tinnitus greater than 12 months\n\n          5. MML >= 7 dB (decibel)\n\n          6. Have tinnitus score of 40 or greater on the Tinnitus Handicap Questionnaire; (THQ)\n\n          7. No tinnitus treatment for at least 4 weeks prior to study entry.\n\n          8. Willing and able to understand and comply with all study-related procedures during\n             the course of the study\n\n        Exclusion Criteria:\n\n          1. Acute or intermittent tinnitus\n\n          2. Severe hearing loss in any ear, as defined as more than an 80 dB HL (decibels hearing\n             level) at frequencies from 250 Hz. to 8,000 Hz.\n\n          3. Meniere's disease, ear tumors, or evidence of active middle ear disease (such as\n             fluid, infection, tumor, mass)\n\n          4. Any other implanted device such as a pacemaker or other neurostimulator; any other\n             investigational device or drug\n\n          5. Pregnant or plan on becoming pregnant or breastfeeding during the study period\n\n          6. Currently require, or likely to require, MRI or diathermy during the study duration\n\n          7. History of adverse reactions to anesthetics (e.g., lidocaine) that in the\n             Investigator's opinion make surgery too risky\n\n          8. Beck Depression Inventory (BDI) of 30 or greater\n\n          9. Any other form of tinnitus treatments (e.g. Herbal medication, acupuncture or\n             chiropractic medicine) are not allowed during the study.\n\n         10. Any drug known to mimic, increase or decrease release or removal of a diffuse\n             neuromodulator, such as norepinephrine, dopamine, serotonin, benzodiazepines, and\n             acetylcholine is not allowed, as well as any psychoactive medications.\n\n         11. Significant cardiac history\n\n         12. Use of any medication known to cause or increase tinnitus, such as NSAIDS (ibuprofen,\n             naproxen, nabumetone, etc.), aspirin and other salicylates, furosemide (Lasix) and\n             other \"loop\" diuretics, \"mycin\" antibiotics such as vancomycin, quinine and related\n             drugs, and chemotherapy agents such as cisplatin.\n\n         13. Involvement in litigation (e.g., worker's compensation claim and/or receiving\n             disability benefits related to tinnitus and/or hearing loss)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "22 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962558", 
            "org_study_id": "MT-T-02", 
            "secondary_id": "2U44DC010084-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "VNS Treatment", 
                "description": "VNS is given in brief bursts over a 2.5 hour period.  The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.", 
                "intervention_name": "VNS Treatment", 
                "intervention_type": "Device", 
                "other_name": [
                    "VNS paired with tones", 
                    "Serenity System"
                ]
            }, 
            {
                "arm_group_label": "VNS Control", 
                "description": "This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.", 
                "intervention_name": "VNS Control", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Tinnitus", 
            "Medical Device", 
            "Randomized", 
            "Vagus Nerve Stimulation"
        ], 
        "lastchanged_date": "March 6, 2014", 
        "link": {
            "description": "Link to study website", 
            "url": "http://www.tinnitustrial.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Iowa City", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "52242"
                    }, 
                    "name": "U. Iowa"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14214"
                    }, 
                    "name": "U. Buffalo"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75235"
                    }, 
                    "name": "UT Dallas"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Blinded Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus vs. VNS With Unpaired Tones", 
        "other_outcome": [
            {
                "description": "Assess the change in BDI score for both groups and compare between the groups.", 
                "measure": "Beck Depression Inventory (BDI)", 
                "safety_issue": "Yes", 
                "time_frame": "6-weeks"
            }, 
            {
                "description": "Assess the change in STAI score for both groups and compare between the groups.", 
                "measure": "State-Trait Anxiety Inventory (STAI)", 
                "safety_issue": "Yes", 
                "time_frame": "6-weeks"
            }, 
            {
                "description": "Assess the change in TFI score for both groups and compare between the groups.", 
                "measure": "Tinnitus Functional Index (TFI)", 
                "safety_issue": "No", 
                "time_frame": "6-weeks"
            }
        ], 
        "overall_contact": {
            "email": "studies@microtransponder.com", 
            "last_name": "W Brent Tarver"
        }, 
        "overall_official": {
            "affiliation": "MicroTransponder Inc.", 
            "last_name": "W Brent Tarver, BSEE", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess the number of serious adverse events during the study, and compare between groups to indicate if there are more in the treatment group than the control group.", 
            "measure": "Number of Serious Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "6-weeks"
        }, 
        "reference": [
            {
                "PMID": "23099209", 
                "citation": "Engineer ND, M\u00f8ller AR, Kilgard MP. Directing neural plasticity to understand and treat tinnitus. Hear Res. 2013 Jan;295:58-66. doi: 10.1016/j.heares.2012.10.001. Epub 2012 Oct 23. Review."
            }, 
            {
                "PMID": "21228773", 
                "citation": "Engineer ND, Riley JR, Seale JD, Vrana WA, Shetake JA, Sudanagunta SP, Borland MS, Kilgard MP. Reversing pathological neural activity using targeted plasticity. Nature. 2011 Feb 3;470(7332):101-4. doi: 10.1038/nature09656. Epub 2011 Jan 12."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962558"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess the number of adverse events during the study, and compare between groups to indicate if there are more in the treatment group than the control group.", 
                "measure": "Number of Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "6-weeks"
            }, 
            {
                "description": "Asses the change in minimum masking level (MML) for both groups and compare between the groups.", 
                "measure": "Minimum masking level (MML) in units of dB (decibels)", 
                "safety_issue": "No", 
                "time_frame": "6-weeks"
            }, 
            {
                "description": "Assess the change in THI score for both groups and compare between the groups.", 
                "measure": "Tinnitus Handicap Inventory (THI)", 
                "safety_issue": "No", 
                "time_frame": "6-weeks"
            }, 
            {
                "description": "Assess the change in THQ score for both groups and compare between the groups.", 
                "measure": "Tinnitus Handicap Questionnaire (THQ)", 
                "safety_issue": "No", 
                "time_frame": "6-weeks"
            }
        ], 
        "source": "MicroTransponder Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Deafness and Other Communication Disorders (NIDCD)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "MicroTransponder Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}